GlaxoSmithKline (GSK) Earns Hold Rating from Deutsche Bank
Deutsche Bank reissued their hold rating on shares of GlaxoSmithKline (LON:GSK) in a research note issued to investors on Tuesday. Deutsche Bank currently has a GBX 1,525 ($19.93) price target on the stock.
A number of other equities research analysts have also issued reports on GSK. Credit Suisse Group set a GBX 1,600 ($20.91) price target on shares of GlaxoSmithKline and gave the stock a neutral rating in a report on Tuesday. HSBC cut their price target on shares of GlaxoSmithKline from GBX 2,030 ($26.53) to GBX 2,000 ($26.13) and set a buy rating on the stock in a report on Wednesday, November 28th. Liberum Capital lowered shares of GlaxoSmithKline from a buy rating to a hold rating and raised their price target for the stock from GBX 1,630 ($21.30) to GBX 1,700 ($22.21) in a report on Thursday, August 30th. Cfra set a GBX 1,620 ($21.17) price target on shares of GlaxoSmithKline and gave the stock a neutral rating in a report on Tuesday. Finally, Goldman Sachs Group set a GBX 1,900 ($24.83) price target on shares of GlaxoSmithKline and gave the stock a buy rating in a report on Monday. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company’s stock. GlaxoSmithKline presently has an average rating of Hold and a consensus target price of GBX 1,512.99 ($19.77).
GSK stock opened at GBX 1,433.40 ($18.73) on Tuesday. GlaxoSmithKline has a 52 week low of GBX 1,235.20 ($16.14) and a 52 week high of GBX 1,724.50 ($22.53).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: What does EPS mean?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.